Prometheus Biosciences stock ended after a USD 10.8 billion deal

Prometheus Biosciences stock became a historical ticker after Merck completed its acquisition of the biotechnology company in June 2023. The transaction paid USD 200.00 per share and valued the San Diego-based developer of inflammatory bowel disease therapies at USD 10.8 billion, according to Edgepedia.

Merck paid USD 200.00

The deal converted each outstanding Prometheus share into a cash payment of USD 200.00. The transaction closed in June 2023, after Merck agreed to acquire the company and make it a wholly owned subsidiary, according to Edgepedia.

The offer represented a 75.00 percent premium to Prometheus' USD 114.01 closing price before the announcement. That comparison explains why the former RXDX listing became a transaction story rather than an operating public-company stock story.

RXDX became a former Nasdaq listing

Investing.com identifies RXDX as the former Nasdaq symbol for Prometheus Biosciences and labels its displayed quotation as historical data. The page also identifies the company under ISIN US74349U1088, so the requested ISIN is omitted from this article.

Prometheus focused on precision-medicine products for inflammatory bowel disease, pairing drug development with diagnostic research. Its lead program, PRA023, targeted TL1A, a biological pathway relevant to ulcerative colitis and Crohn's disease, according to Edgepedia.

The transaction defines the stock history

The key figures are the USD 200.00 cash consideration, the USD 10.8 billion equity value and the 75.00 percent premium to USD 114.01. Together, they mark the completed change from an independent Nasdaq-listed biotech into a wholly owned Merck business.